Table 3.
Relation of Aβ40 level to medication at baseline
| Group 1 | pg/ml | pg/ml | |||
| n | Aβ40 | Users | Non-users | ||
| Sex, female | 148 | – | |||
| Smoking | 21 | – | |||
| Coronary heart disease | 61 | ↑ | p=0.035 | 188 (105–360) | 176 (0–780) |
| Diabetes | 22 | – | |||
| Anticoagulants | 16 | ↑ | p=0.038 | 198 (144–360) | 176 (0–780) |
| Non-steroidal anti-inflammatory drugs | 22 | – | |||
| Acetylsalicylic acid | 62 | ↑ | p=0.004 | 194 (0–278) | 175 (0–780) |
| Dipyridamole | 12 | ↑ | p=0.016 | 208 (156–278) | 176 (0–780) |
| Antidiabetics* | 13 | ↑ | p=0.003 | 219 (161–426) | 179 (0–780) |
| Lipid-lowering agents | 24 | – |
Insulin and oral antidiabetics.